RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS (RESTYLE- HCM STUDY)
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2015
At a glance
- Drugs Ranolazine (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Therapeutic Use
- Acronyms RESTYLE-HCM
- Sponsors Menarini
- 22 Sep 2012 Planned End Date changed from 3 Jan 2013 to 19 Jan 2013 as reported by European Clinical Trials Database record.
- 14 Jul 2012 Additional location [Germany] identified as reported by as reported by European Clinical Trials Database.
- 22 Mar 2012 New trial record